Proving the Value of Real-World Data to Stakeholders

As more and more pharma companies, payer groups, and regulatory bodies accept the growing use of real-world data (RWD) in decision-making, it is becoming ever more important to demonstrate the resource’s value to stakeholders. In a new article by Barbara Arone MS, VP of Real World Solutions at IQVIA, learn about proving the value of RWD and the real-world evidence (RWE) generated from it.

According to Arone, “Examples of how organizations can benefit from and prove the value of RWE include illustrating market size, unmet needs, morbidity and mortality, and patient burden (e.g., financial, social, psychological, etc.). Additionally, RWE will be a vital tool for clinical trial feasibility, granular patient matching based on phenotypic biomarkers, and regulatory approval for single-arm trial drug development. However, to gain the most value from and investment in RWE, understanding its proper application and collaborating with industry stakeholders will be key. ”

To read more, click here.

(Source: Contract Pharma, November 7^th, 2022)